CIGB-552

CIGB-552 is a synthetic anti-tumor peptide developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB). It functions by interacting with and upregulating the COMM domain-containing protein 1 (COMMD1), which subsequently inhibits the NF-κB signaling pathway. This inhibition occurs through the COMMD1-mediated ubiquitination of the RELA (p65) subunit and the stabilization of the inhibitory protein NFKBIA (IκBα). Furthermore, CIGB-552 suppresses angiogenesis by inhibiting HIF1A and induces oxidative stress in cancer cells by disrupting SOD1 activity. Clinical development has reached Phase I, where it was evaluated in patients with advanced solid tumors, including colorectal cancer and soft tissue sarcomas, demonstrating a manageable safety profile and signs of stable disease.